Karen J. Wilson
Director · Elicio Therapeutics, Inc.
IndividualBuying only
- 2024
- Sep 2, 2026
- 8
Other insiders active in the same sector
No other insider has filed at Karen J. Wilson's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Daniel Allen Gold - $147.38M in ROIV purchases and sales in the last 12 months
- ULSE Inc. - $146.25M in ULS purchases and sales in the last 12 months
- Michael Benkowitz - $135.23M in UTHR purchases and sales in the last 12 months
- Andrew T. Kaplan - $134.38M in KLRA purchases and sales in the last 12 months
- BAIN CAPITAL INVESTORS LLC - $134.38M in KLRA purchases and sales in the last 12 months
- Fairmount Funds Management LLC - $133.53M in APGE purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Karen J. Wilson?
Karen J. Wilson is a corporate insider, tracked as Director of Elicio Therapeutics, Inc. (ELTX). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Karen J. Wilson submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Karen J. Wilson been buying or selling stock?
Recorded transactions: 4 open-market purchases ($55K) and 0 open-market sales across all tracked filings.
